FREDERICK, Md., March 21 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , and the Lahey Clinic jointly announced today a three-year program to study the effects of ActiPatch on a variety of soft tissue injuries and related medical conditions.
The internationally renowned Lahey Clinic of Boston, whose faculty is affiliated with the Medical Schools of Harvard and Tufts, has committed to initiating a number of double-blind clinical studies on ActiPatch in the areas of plastic surgery, orthopedics and chronic wound care. Results from these clinical trials will be submitted to the Food and Drug Administration for expanded indications for the use of ActiPatch.
Dr. Lawrence Michaelis, Chairman of the BioElectronics' Medical Advisory Board commented, "This partnership is a great opportunity to accelerate our clinical studies as the Lahey Clinic has a reputation for exceptional clinical and research capability, a wealth of experience in clinical trials, and the talent to deliver practical and meaningful results. The leadership of Dr. Jeffery Weinzweig in this endeavor is going to be particularly helpful to us."
The new ActiPatch clinical program will be spearheaded by Dr. Jeffrey Weinzweig, Chairman of the Department of Plastic Surgery for the Lahey Clinic and a member of the Medical Advisory Board of BioElectronics. Dr. Weinzweig has authored more than a hundred and fifty scientific papers and chapters on various topics within the plastic surgery, hand surgery, and craniofacial surgery arena. He is also an expert on the care of chronic wounds. Dr. Weinzweig is currently editing his fifth textbook and serves as Director of the Institute of Craniomaxillofacial Surgery and Director of Research of the Craniofacial Biology & Tissue Engineering Laboratory at Lahey and has lectured to medical professionals around the world.
"We are thrilled and quite fortunate to have a partnership with a medical research institution of the caliber of the Lahey Clinic. The talents of the Lahey team greatly enhance our mission in the clinical study of our breakthrough technology," said Bioelectronics' Executive President and CEO Andrew J. Whelan.
ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics CorporationCONTACT: Andrew J. Whelan, President & CEO, or Thomas O'Connor, EVPOperations & COO, both of BioElectronics Corporation, +1-301-644-3906, Fax:+1-301-644-3939, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com/
